Retinal Gene Therapy Market Industry Research, Segmentation, Key Players Analysis and Forecast to 2029

This Retinal Gene Therapy market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study.

This study is one of the most comprehensive documentation that captures all the facets of the evolving Retinal Gene Therapy market.

Retinal gene therapy is performed for inherited retinal diseases. Gene therapy can improve the vision impairment caused by mutation in RPE65 gene.  The recently launched retinal gene therapy, Luxturna, is being used for patient with Leber congenital amaurosis type 2, it is a form of inherited disease which causes impaired vision at birth leading to a more progressive degeneration.

There are many retinal gene therapy clinical trials present at the moment using recombinant viruses.

Retinal Gene Therapy Market: Drivers and Restraints

Retinal gene therapy is projected to grow at an enormous rate. Retina is a desirable target for gene therapy, it is growing because of it being an irreplaceable part of human body. Retinal gene therapy market is expected to experience new entrants, with promising candidates in clinical phases of drug approval.

The market is expanding exponentially over the last year, with many drugs in ongoing clinical trials. Currently, retinal gene therapy market have only one FDA approved product, Luxturna from Spark Therapeutics. The product received FDA approval in year 2017, starting an era of possible retinal gene therapy.

Recently it was announced that Roche is interested in purchasing the company for approximately US$ 4.8 Bn, the interests from leading pharmaceutical manufacturers highlight the potential within this retinal gene therapy market. The market is influenced with a high prevalence of Stargardt disease, a common type of inherited retinal dystrophies, prevalence of around 1 in 12,000.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-10246

Accurate and early diagnosis can lead to a better market structure, with patients willing to enrol in the clinical trials process. More number of approved products can lead to a more convenient reach for patients. The availability of the approved therapy is also minimal in emerging economies, if available, emerging countries can be the most attractive segments in terms of value addition.

Qualified surgeons and standard infrastructure is required for retinal gene therapy procedures, it involves a surgical and delivery plan with great precision. Socio-economic condition can lead to the late entry of such modality in emerging countries. But, if treatment is present for a previously stated incurable disorder, it should reach out to as many as possible.

Cost associated with the retinal gene therapy is considerably high as observed in other gene therapy procedures. The cost of retinal gene therapy is estimated to be around US$ 450,000 to US$ 850,000 in the US.